ENTRUST-GLOBAL
14.6.2021 21:15:03 CEST | Business Wire | Press release
The Blue Sky Aviation strategy managed by EnTrust Global (“EnTrust”), a leading alternative asset management firm, and funds managed by Strategic Value Partners, LLC and its affiliates ("SVPGlobal"), a global investment firm, have today announced the completion of the acquisition of the Aviation Investment and Asset Management business from DVB Bank Group, resulting in the formation of Deucalion Aviation Limited (“Deucalion” or the “Company”). Deucalion is an innovative global platform with world class aviation expertise and the ability to invest across the capital spectrum to provide solutions to airlines and aviation investors.
Led by Jon Skirrow and Stephan Sayre, with the support of EnTrust Global and SVPGlobal, Deucalion is a servicer for over 170 aircraft on lease to 86 airlines with clients including banks, investors, financiers and lessors.
Jon Skirrow, Co-CEO & COO said: “This new investment creates a platform with collaboration at its heart to enable us to continue and expand our world-leading services to airlines and investors”.
Stephan Sayre, Co-CEO & CIO added: “EnTrust and SVPGlobal share our vision to provide transformational financing and investment solutions. Together, we will be able to significantly strengthen our offering of innovative financing solutions to airline and leasing clients globally in the current environment”.
Victor Khosla, Founder & CIO of SVPGlobal, said: “Deucalion is a top-tier aviation platform with an experienced management team, a global footprint, and an impressive track record that spans almost two decades of managing complex aviation projects. We look forward to working with the Deucalion team as we continue to capitalize on the current market opportunity.”
John Morabito, Senior Managing Director and Portfolio Manager of EnTrust Global’s Blue Sky Aviation strategy, said: “The Deucalion team, led by Jon and Stephan, has extensive institutional knowledge and experience in the aviation industry. By combining our groups’ strengths, relationships, and capabilities, we are positioned to provide differentiated financing solutions to the global aviation industry.”
About Deucalion Aviation Limited
Deucalion Aviation Limited is a servicer for over 170 aircraft on lease to 86 airlines with clients including banks, investors, financiers and lessors and is headquartered in London with offices in Europe, Asia and America. Led by Jon Skirrow and Stephan Sayre, the Deucalion team is composed of over 45 marketing, commercial finance, origination and technical professionals with experience throughout multiple aviation cycles. www.deucalion.com
About EnTrust Global
EnTrust Global is a leading alternative asset management firm with approximately $19.5 billion in total assets.* Co-founded in 1997 by Chairman and CEO Gregg S. Hymowitz, the firm manages assets for over 500 institutional investors representing 48 countries and has approximately $11 billion in customized strategic partnerships. EnTrust Global offers a diverse range of alternative investment opportunities across strategies, including private debt and real assets as well as opportunistic co-investments and direct investments. EnTrust Global has 10 offices worldwide and is headquartered in New York and London.
*As of March 31, 2021. Based on estimates and includes assets under advisement and mandates awarded but not yet funded.
About Strategic Value Partners
SVPGlobal is a global investment firm focused on special situations and private equity opportunities with more than $15 billion in assets under management. The firm, established by Victor Khosla in 2001, uses a combination of sourcing, financial, and operational expertise. SVP has 128 employees, including 50 investment professionals, across its main offices in Greenwich (CT), London and Tokyo.
Learn more at www.svpglobal.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210614005754/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom